The binding of STING agonists to these nanoparticles reduced reduce tumor burden by > 50% - 80% and significantly increased median survival in melanoma (YUMM1.7) and malignant breast adenoma (E0771) models (101). This evidence concerns the gene STING1 and melanoma.